In murine models of fibrosarcoma (Sa1N) and colon carcinoma (CT26), injection of a single dose of DMAbs (100 μg) encoding murine anti-CTLA-4 resulted in complete responses and suppressed tumor growth similar to 3 doses of recombinant anti-CTLA-4 treatment at 10 ug/injection. Here, CTLA4 is linked to neoplasm.